Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Image
  • Published:

Infographic: Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW and RAINBOW Extension Study)

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

Authors

Contributions

VM - extracted key data, designed infographic with text, refined content. LF - reviewed, fed back and approved final infographic. AK - reviewed, fed back and approved final infographic. DJF - reviewed, fed back and approved final infographic.

Corresponding author

Correspondence to Venughanan Manikavasagar.

Ethics declarations

Competing interests

LF and DJF are members of the Eye editorial board. The authors declare no other conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manikavasagar, V., Faes, L., Kennedy, A. et al. Infographic: Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW and RAINBOW Extension Study). Eye (2026). https://doi.org/10.1038/s41433-025-04187-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41433-025-04187-1

Search

Quick links